10x Genomics, Inc. (TXG)

Market Cap	3.20B +177.8%
Revenue (ttm)	642.82M +5.2%
Net Income	-43.54M
EPS	-0.35
Shares Out	127.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,229,801
Open	24.19
Previous Close	23.58
Day's Range	23.95 - 25.29
52-Week Range	7.25 - 25.29
Beta	2.17
Analysts	Hold
Price Target	17.61 (-29.64%)
Earnings Date	May 7, 2026

About TXG

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium p...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Sep 12, 2019
• Employees: 1,178
• Stock Exchange: NASDAQ
• Ticker Symbol: TXG
• Website: https://www.10xgenomics.com

Financial Performance

In 2025, 10x Genomics's revenue was $642.82 million, an increase of 5.25% compared to the previous year's $610.79 million. Losses were -$43.54 million, -76.16% less than in 2024.

Analyst Summary

According to 15 analysts, the average rating for TXG stock is "Hold." The 12-month stock price target is $17.61, which is a decrease of -29.64% from the latest price.

Price Target

$17.61

(-29.64% downside)

Analyst Consensus: Hold